Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

  • days left to enroll
  • participants needed
  • sponsor
    ProMedica Health System
Updated on 23 January 2021


Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Condition Hypercalcemia, Hyperparathyroidism, Primary hyperparathyroidism, Hyperparathyroidism (Pediatric)
Treatment Calcitonin
Clinical Study IdentifierNCT03935984
SponsorProMedica Health System
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of primary hyperparathyroidism
Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study
Patient desires surgical intervention for treatment of PHPT
No contraindications to 99mTC-Sestamibi
No contraindications to treatment with calcitonin
Serum calcium level prior to non-localizing SPECT-CT is 10.5 mg/dL
Patient consents to participate and undergo second SPECT-CT for purposes of research

Exclusion Criteria

Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary
Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT
Allergy to calcitonin
Hypocalcemia (contraindication to calcitonin)
Vitamin D deficiency (contraindication to calcitonin)
Previous treatment with radioactive iodine
New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc. must be taken at time of index scan and research scan)
Lithium exposure within one year of SPECT-CT (index and research scans)
Secondary hyperparathyroidism
Benign familial hypocalciuric hypercalcemia
Known malignancy, particularly multiple endocrine neoplasia
New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the time of index scan and second scan)
Currently taking calcium channel blockers
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note